

Pharmacy BULLETIN BOARD

Industry Issue ■ Monday May 25, 2015

Pr **Dymista**[®]

 (Azelastine Hydrochloride/Fluticasone Propionate)
137 mcg/50mcg per metered spray

Meda Pharmaceuticals Ltd. is pleased to inform you that DYMISTA[®] nasal spray is available in Canada.

DYMISTA[®] (azelastine hydrochloride/fluticasone propionate) is indicated for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults and adolescents aged 12 years and older for whom monotherapy with either antihistamines or intranasal corticosteroids is not considered sufficient.

To place an order for DYMISTA, please contact the following wholesalers: McKesson, McMahon, Familiprix.

For any questions on how to order you may also contact Meda order desk at 1-800-268-4937 or fax : 905-879-0123.

Product Name	Product Code	UPC Code	DIN	Unit Size
DYMISTA [®] (Nasal Spray)	CA2071112	627843453154	02432889	120 Sprays per bottle

To learn more about DYMISTA[®], please contact Meda Pharmaceuticals Ltd. at 1-855-400-MEDA(6332).

DYMISTA[®] is a registered trademark of Meda AB.



Odan Laboratories is pleased to introduce their new sodium chloride product:

ODAN-SODIUM CHLORIDE

OPHTHALMIC OINTMENT USP

Odan-Sodium Chloride[™] ophthalmic ointment is indicated for the temporary relief of corneal edema

The only equivalent to Muro-128[†]

Product	Format	Odan	K & F	McKesson
Odan-Sodium Chloride Ointment NPN 80046696	3.5 g	12735	149285	067490
Odan-Sodium Chloride Solution* NPN 80046737	15 mL	12515	149153	067456

*Covered by the British-Columbia formulary

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at info@odanlab.com.




www.odanlab.com

*Odan Laboratories Ltd., Montreal, QC, Canada H9R 2Y6

[†]Muro 128 is a registered trademark of Bausch & Lomb

FROM THE NEWSWIRE

QUEBEC CITY: Opsens inc. is pleased to announce the first use of the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), by Dr. Nico Pijls in Eindhoven, the Netherlands. Opsens' FFR products are designed to optimize the diagnosis and guide the treatment of patients with coronary heart disease.

TORONTO: There are major differences across Ontario's long-term care homes in the percentage of residents who are being prescribed antipsychotic medications, according to Looking for Balance, a report from Health Quality Ontario (HQO), the provincial advisor on health care quality.

QUEBEC CITY: DiagnoCure Inc. reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA).

OAKVILLE, ON: ENTIVIO[™] (vedolizumab), a new biologic treatment to treat ulcerative colitis (UC), one of the two most common types of inflammatory bowel disease, is now available in Canada.

MONTREAL: A new study published by the team of Naguib Mechawar, Ph.D., a researcher at the Douglas Institute (CIUSSS de l'Ouest-de-l'île-de-Montréal) and Associate Professor in the Department of Psychiatry at McGill University, suggests that the integration of new neurons in the adult brain is a phenomenon more generally compromised in the brains of depressed patients. This new work confirms that neurogenesis in the human olfactory bulb is a marginal phenomenon in adults. These findings shed light on the special features of the human brain.

OTTAWA: Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in public drug plans, according to a new IMS Brogan report commissioned by Rx&D. Overall, the report ranks Canada 16 out of 18 similar OECD countries.

OTTAWA: CSL Behring has announced that Health Canada has approved a new, low-volume presentation size for the existing indications of Berinert[®], a human plasma-derived, pasteurized and nanofiltered C1-esterase inhibitor (C1-INH) concentrate. The new Berinert[®] 1500 IU format is reconstituted with 3 mL vial of Sterile Water for Injection (Diluent). In Canada, Berinert[®] is indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) of moderate to severe intensity. Berinert[®], licensed since 2010, is the first C1-INH available in Canada.



Lower Cost Generic Alternative to Pennsaid®¹!!!

PrTaro-Diclofenac

Diclofenac Sodium Topical Solution 1.5%

Taro-Diclofenac Topical Solution 1.5% is Available for Immediate Shipping!!!

- Bioequivalent to Pennsaid®¹
- Interchangeable with Pennsaid (OFI) in Ontario
- High Quality, Lower Price Alternative

Topical Solution 1.5%

DIN	Size	UPC	Wholesaler			
			Mckesson	K&F	Procurity	McMahon
02420988	2 x 60 mL	063691073517	060770	147411	256323	10071421
	150 mL	063691073548	060771	147409	256480	10071400

For further information, or to place an order for **Taro-Diclofenac topical solution 1.5%**, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at **www.taro.ca**.

¹Data on file, Taro Pharmaceuticals Inc.
²PrTaro-Diclofenac Product Monograph.
 © Pennsaid is a registered trademark of Nuvo Research Inc.
 TARO is a registered trademark of Taro Pharmaceuticals Inc.



Lower Cost Generic Alternative to Tegretol®¹

PrTaro-Carbamazepine

Carbamazepine Tablets 200mg

- Bioequivalent to Tegretol®¹
- High Quality, Lower Price Alternative
- Anticonvulsant; Symptomatic Relief of Trigeminal Neuralgia; Antimanic²

Form	Strength	DIN	Size	UPC	Wholesaler			
					Mckesson	K&F	Procurity	McMahon
Tablet	200 mg	02407515	100	063691071664	071730	147882	269948	10071282
			500	063691072671	063139	147883	279226	10071281

For further information, or to place an order for **Taro-Carbamazepine 200 mg Tablets**, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at **www.taro.ca**.

¹Data on file, Taro Pharmaceuticals Inc.
²PrTaro-Carbamazepine Product Monograph.
 © Tegretol is a registered trademark of Novartis Pharmaceuticals Canada Inc.
 TARO is a registered trademark of Taro Pharmaceuticals Inc.

**To include your communication in the next issue,
 please contact: Health Response**

T: 416-863-5403 | F: 416-863-9620 |
hrc@healthresponse.ca

Next Issue: Monday June 8th, 2015
 Deadline: Thursday June 4th, 2015